Verseon to Present New Preclinical Results for Novel Class of Oral Anticoagulants at the 3rd International Conference on Heart & Brain
FREMONT, Calif. – Verseon Corporation (AIM: VSN) will present a poster featuring new data for several promising oral anticoagulant drug candidates on February 25th at the 3rd International Conference on Heart & Brain (ICHB) in Paris. Verseon's candidates represent a novel class of highly selective direct thrombin inhibitors (DTIs) with superior preclinical bleeding risk profiles when compared to those of the existing oral NOACs.
Verseon, a technology-based pharmaceutical company, uses its proprietary computational drug discovery platform to devise novel therapeutics for unmet medical needs. The Company's new class of potent, highly selective DTIs has demonstrated excellent results in preclinical efficacy studies and has pharmacokinetic properties suitable for oral dosing.
"The new results we are presenting at ICHB include data from an additional comprehensive preclinical thrombosis model that further confirms the efficacy of Verseon's drug candidates," said Anirban Datta, Director of Discovery Biology at Verseon, "Our anticoagulants continue to show positive results as the program progresses."
For further information please contact
|Verseon Corporation||+1 (510) 225 9000|
|Arthur Shmurun / Amy Thai|
|Vane Percy & Roberts (Media Enquiries)||+44 (0) 1737 821890|
|Simon Vane Percy|
|Abchurch Communications Ltd (PR Advisers)||+44 (0) 20 7398 7719|
|Jamie Hooper / Alex Shaw|
Verseon is a technology-based pharmaceutical company that employs its proprietary computational drug discovery platform to develop novel therapeutics for today's challenging diseases. Verseon's platform can consistently design novel drugs that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.